# Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

> **NCT07445347** · — · ENROLLING_BY_INVITATION · sponsor: **Poitiers University Hospital** · enrollment: 111 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia (HHT)
- Pulmonary Hypertension
- Bevacizumab

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07445347
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-15
- **Primary completion:** 2026-06
- **Final completion:** 2026-11
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07445347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07445347, "Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07445347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*